QR Kod

Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity

Abstract Tumor heterogeneity is predicted to confer inferior clinical outcomes with precision-based strategies, however, modeling heterogeneity in a manner that still represents the tumor of origin remains a formidable challenge. Sequencing technologies are limited in their ability to identify rare...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Jeremy D. Kratz, Shujah Rehman, Katherine A. Johnson, Amani A. Gillette, Aishwarya Sunil, Peter F. Favreau, Cheri A. Pasch, Devon Miller, Lucas C. Zarling, Austin H. Yeung, Linda Clipson, Samantha J. Anderson, Alyssa K. Steimle, Carley M. Sprackling, Kayla K. Lemmon, Daniel E. Abbott, Mark E. Burkard, Michael F. Bassetti, Jens C. Eickhoff, Eugene F. Foley, Charles P. Heise, Randall J. Kimple, Elise H. Lawson, Noelle K. LoConte, Sam J. Lubner, Daniel L. Mulkerin, Kristina A. Matkowskyj, Cristina B. Sanger, Nataliya V. Uboha, Sean J. Mcilwain, Irene M. Ong, Evie H. Carchman, Melissa C. Skala, Dustin A. Deming
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Portfolio 2025-04-01
Seri Bilgileri:Scientific Reports
Konular:
Organoids
Clonal heterogeneity
Colorectal cancer
Targeted therapy
EGFR
Online Erişim:https://doi.org/10.1038/s41598-025-96204-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller